Table 1 Background of esophageal cancer patients and HPV16 integration
From: Integration of human papillomavirus 16 in esophageal carcinoma samples
Background | HPV16 positive(n = 79) | Samples (n = 189) | Integrated | Without | X 2 | P a |
|---|---|---|---|---|---|---|
integrated | ||||||
sex | 0.06 | >0.05 | ||||
male | 55 | 136 | 7 | 48 | ||
female | 21 | 53 | 2 | 19 | ||
age (year old) | 1.38 | >0.05 | ||||
≤ 45 | 18 | 41 | 1 | 17 | ||
46–64 | 28 | 70 | 3 | 25 | ||
≥ 65 | 30 | 78 | 5 | 25 | ||
differentiated type | 0.09 | >0.05 | ||||
well differentiated | 11 | 30 | 1 | 10 | ||
moderately differentiated | 49 | 104 | 6 | 43 | ||
poorly differentiated | 16 | 55 | 2 | 14 | ||
pathological stages | 2.99 | >0.05 | ||||
early stage | 25 | 98 | 2 | 23 | ||
middle stage | 40 | 63 | 4 | 36 | ||
late stage | 11 | 28 | 3 | 8 | ||
Total | 76 | 189 | 9 | 67 |